If you had bought Givaudan on 12 November 2025, the last twelve months would now look very different. For Givaudan shareholders, the return over the past year was 21.5%, including dividends. Yet at the decision point, analysts were split between a CEO transition story with higher growth assumptions and a harsher view focused on regulatory pressure and raw material costs. Which of those competing pictures would you have trusted more with your own capital at risk, and why?
If the move has made Givaudan harder to judge, start where the gap is still open and scan 193 high quality undervalued stocks.
The Two Givaudan Stories Investors Had To Weigh
The shares cost CHF3,446 at the start of the period, and anyone looking at Givaudan then faced two very different but plausible stories.
On the upbeat side, one analyst group saw a CEO transition leading to stronger growth and assigned a Fair Value of CHF4,082, a level they viewed as implied by assumptions such as 4.4% revenue growth.
The cautious camp focused on regulatory pressure and rising raw material costs, using a Fair Value of CHF3,200 that rested on lower 3.0% revenue growth assumptions and a 26.6x future P/E.
What The Results Changed For The Givaudan Debate
The clearest new fact for Givaudan was the H1 2026 report. Revenue moved from CHF3,864m in H1 2025 to CHF3,799m in H1 2026, and net income slipped from CHF592m to CHF475m. Net margin fell from 15.3% to 12.5%. That profit squeeze challenged the bullish case for higher, more resilient margins as much as it supported the cautious view, so the evidence cut both ways.
The key assumption to watch in similar stories is margin resilience. When upbeat forecasts lean on richer profitability, track net margin in each result and compare it with the original forecast, not just with the share price move.
What Givaudan's Price Now Asks You To Believe
Givaudan now trades at CHF4,091, up 21.5% over the past year, while the bearish analyst Narrative on Simply Wall St places its Fair Value below that level.
That view leans on a gap between strong Fine Fragrance momentum and weaker Taste & Wellbeing, plus pressure on cash generation and legal costs. Any buyer today is assuming group earnings can grow consistently, so how do those cash flow strains and litigation risks shape that expectation?
"Even though management points to a focus on cash generation and reconfirms ambitions for adjusted free cash flow margins above 12% with a 22 to 25% EBITDA margin range, the recent rise in net working capital to 30.8% of sales and an adjusted free cash flow outflow of CHF 119m in H1 2026 highlight execution risk that further working capital strain, litigation cash effects or higher net investments could restrict cash conversion and constrain future shareholder payouts."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
Go Straight To The Source
By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.
- Company 1 - 38% below our estimate - helps clients address safety, regulatory and failure issues in critical AI projects.
- Company 2 - 20% below our estimate - builds antibiotic-eluting bone grafts surgeons use when hospitals reduce systemic treatments.
- Company 3 - 22% below our estimate - expands elevator modernization and maintenance reach by hiring sales staff to secure contracts.
Those are three of them. See the full list of 199 financially solid companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com